Financial Performance - Operating revenue for the period was CNY 414,469,729.79, representing a 40.19% increase year-on-year[11] - Net profit attributable to shareholders was CNY 11,033,820.63, a decrease of 11.25% compared to the same period last year[11] - Net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 12,665,557.20, an increase of 29.94% year-on-year[11] - Basic earnings per share were CNY 0.008, a decrease of 11.11% compared to the same period last year[11] - The company reported a net loss of ¥1,588,305,774.34 in undistributed profits, which is an improvement from a loss of ¥1,599,339,594.96 in the previous period[39] - The net profit for Q1 2021 was ¥14,101,823.18, a decrease of 7.8% from ¥15,300,816.88 in Q1 2020[49] - The total comprehensive income attributable to the parent company for Q1 2021 was ¥11,033,820.63, compared to ¥12,432,952.63 in Q1 2020[49] - The company's operating profit for Q1 2021 was ¥21,206,725.81, an increase of 19.3% from ¥17,775,356.18 in Q1 2020[49] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 1,557,589,908.88, an increase of 3.58% compared to the end of the previous year[11] - The total assets increased to ¥1,557,589,908.88 from ¥1,503,783,979.79, showing growth in the asset base[28] - The total liabilities increased to ¥1,394,514,877.79 from ¥1,352,823,471.80, indicating a rise in financial obligations[31] - The total liabilities for Q1 2021 were ¥504,700,597.55, down from ¥518,674,312.02 in Q1 2020, showing a decrease of about 2.5%[39] - Long-term borrowings increased to ¥20,000,000.00, reflecting new bank financing during the period[20] Cash Flow - Cash flow from operating activities for the period was significantly improved, with a net cash inflow compared to a net outflow of CNY 738,483,334.77 in the same period last year[11] - The company's operating cash inflow for Q1 2021 was CNY 372,215,605.87, compared to CNY 140,574,602.65 in Q1 2020, representing a significant increase[57] - The net cash flow from operating activities was CNY 9,655,142.09, a turnaround from a negative cash flow of CNY -839,927,332.69 in the same period last year[57] - The ending balance of cash and cash equivalents was CNY 27,794,317.45, down from CNY 62,292,584.53 in the previous year[57] - The company reported a cash balance of CNY 58,065,651.54 at the end of the period, compared to CNY 324,855,027.41 at the end of the previous year[53] Shareholder Information - The number of shareholders at the end of the reporting period was 63,508[17] - The largest shareholder, Wuhu Liantai Investment Management Center, held 10.04% of the shares, amounting to 138,509,529 shares[17] Operating Costs and Expenses - Operating costs rose by 47.58% to ¥348,616,394.99, driven by increased sales volume and rising raw material prices[20] - The company’s management expenses decreased by 31.50% to ¥12,282,611.85 due to enhanced cost control measures[23] - Sales expenses decreased to ¥3,276,477.11 in Q1 2021 from ¥13,769,761.06 in Q1 2020, reflecting cost management efforts[49] - Financial expenses increased by 49.47% to ¥5,902,546.67 due to adjustments in financing structure and increased financing scale[23] - Financial expenses decreased significantly to ¥350,041.11 in Q1 2021 from ¥3,159,343.80 in Q1 2020, indicating improved financial efficiency[49] Government Subsidies - Government subsidies recognized in the current period amounted to CNY 117,307.69, related to a technology bureau project subsidy[15] Research and Development - Research and development expenses for Q1 2021 were ¥1,910,415.28, indicating ongoing investment in innovation[49]
莲花健康(600186) - 2021 Q1 - 季度财报